<DOC>
	<DOCNO>NCT01278576</DOCNO>
	<brief_summary>The study aim compare effectiveness BOTOX-AÂ® ( botulinun toxin A ) place two different injection site , namely proximal portion gastrocnemius ( GCM ) versus midbelly GCM .</brief_summary>
	<brief_title>Botulinum Toxin A Adult Gastrocnemius Muscle Study</brief_title>
	<detailed_description>Previous study use midbelly muscle position motor endplates densely locate . The reason behind method base previous work show band cholinesterase activity locate specific topographical pattern center muscle fiber . These result use landmarks place injection . Current standard guideline recommend botulinum toxin place 4 quadrant midbelly portion gastrocnemius ( GCM ) muscle . However , recent cadaveric research study distribution intramuscular ending GCM suggest high branch density find within upper 20-30 % length calf . Therefore , accordance theory effect botulinum toxin great site intramuscular ending dense , location toxin place would proximal site GCM rather midbelly . 40 recruit patient allocate either intramuscular end target ( ie.upper portion calf ) midbelly target group . Each subject undergo total number 4 assessment ; prior injection 2,4and 8 week post injection .</detailed_description>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Male female , 20 &lt; age &lt; 70 year old Hemiplegia document ischemic hemorrhagic stroke , document CT ( compute tomography ) MRI ( magnetic resonance imaging ) scan Time onset stroke &lt; 24 month Individuals medically stable least 4 week prior study enrollment Confirmed equinovarus spastic hypertonia ankle Spasticity define MAS great grade 1 + Botulinum toxin naive patient Participants complete 10 meter walk test caregiver walk tool assistance within 8 45 second , 2 occasion Participants stable treatment regimen concomitant medication trial period The patient follow medical condition contraindication botulinum toxin exposure ; pregnancy , lactation , neuromuscular disease , aminoglycoside , antibiotic concurrent botulinum toxin treatment Fixed contracture ankle , previous history surgical procedure perform ankle Cognitive deficit disable patient give informed consent procedure Concomitant progression CNS ( central nervous system ) PNS ( peripheral nervous system ) , myopathy , uncontrolled seizure . Underlying CNS insult control stable condition risk progression deterioration patient 's current neurological status . Those multiple sclerosis multiple systemic atrophy exclude Significant cutaneous joint inflammation URI systemic infection would mandate use antibiotic concurrent botulinum toxin injection Anticoagulation treatment INR ( International Normalized Ratio ) great 3.0 Upper extremity spasticity great MAS grade 4 may limit gait function Subjects previous episode motor point block injection use phenol chemodenervating agent Subjects intrathecal baclofen pump</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Muscle spasticity</keyword>
	<keyword>Stroke</keyword>
	<keyword>Botulinum Toxins</keyword>
	<keyword>Lower extremity</keyword>
	<keyword>Ankle</keyword>
</DOC>